multistem emerging drug insight and market forecast

“MultiStem Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about MultiStem for Acute Respiratory Distress Syndrome in seven major markets. A detailed picture of the MultiStem for Acute Respiratory Distress Syndrome in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the MultiStem for Acute Respiratory Distress Syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MultiStem market forecast analysis for Acute Respiratory Distress Syndrome in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Acute Respiratory Distress Syndrome.

Drug Summary

MultiStem—also known as AMI MultiStem, HLCM 051, and PF-05285401—is a patented regenerative product that can promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance. It has demonstrated the therapeutic potential for the treatment of inflammatory and immune disorders, neurological conditions, and cardiovascular disease, as well as other areas. It represents a unique “off-the-shelf” stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression.

MultiStem is under development by Athersys for the treatment of ARDS. It is also under investigation in Phase III for Ischemic Stroke and Phase II for Acute Myocardial Infarction, Phase I stage for the treatment of Solid Organ Transplant Support, and the preclinical stage for the treatment of Traumatic Brain Injury, Multiple Sclerosis, and Spinal Cord Injury. Cell therapy is also commercialized for Bone Allograft.

Healios is also investigating Athersys clinical products under an exclusive licensing agreement by acquiring rights to develop and distribute Athersys’ proprietary stem cell product MultiStem to treat ARDS in Japan.

The company is currently enrolling in a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in Covid-19 induced ARDS patients. This trial is a multicenter study with an open-label, single active treatment arm for cohort 1 followed by a double-blind, randomized, placebo-controlled phase II/III portion. The Company’s program evaluating the administration of MultiStem for the treatment of ARDS was recently granted Fast Track designation by the FDA based on the promising Phase I/II data from its previously completed MUST-ARDS trial.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MultiStem description, mechanism of action, dosage and administration, research and development activities in Acute Respiratory Distress Syndrome.
• Elaborated details on MultiStem regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MultiStem research and development activities in Acute Respiratory Distress Syndrome across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MultiStem.
• The report contains forecasted sales of MultiStem for Acute Respiratory Distress Syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Acute Respiratory Distress Syndrome.
• The report also features the SWOT analysis with analyst views for MultiStem in Acute Respiratory Distress Syndrome.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MultiStem Analytical Perspective by DelveInsight

• In-depth MultiStem Market Assessment

This report provides a detailed market assessment of MultiStem for Acute Respiratory Distress Syndrome in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• MultiStem Clinical Assessment

The report provides the clinical trials information of MultiStem for Acute Respiratory Distress Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Acute Respiratory Distress Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MultiStem dominance.
• Other emerging products for Acute Respiratory Distress Syndrome are expected to give tough market competition to MultiStem and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MultiStem in Acute Respiratory Distress Syndrome.
• Our in-depth analysis of the forecasted sales data of MultiStem from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MultiStem in Acute Respiratory Distress Syndrome.

Key Questions

• What is the product type, route of administration and mechanism of action of MultiStem?
• What is the clinical trial status of the study related to MultiStem in Acute Respiratory Distress Syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MultiStem development?
• What are the key designations that have been granted to MultiStem for Acute Respiratory Distress Syndrome?
• What is the forecasted market scenario of MultiStem for Acute Respiratory Distress Syndrome?
• What are the forecasted sales of MultiStem in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to MultiStem for Acute Respiratory Distress Syndrome?
• Which are the late-stage emerging therapies under development for the treatment of Acute Respiratory Distress Syndrome?